Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
InoviqASX:IIQ 27 PS Ratio is 40.00 as of Jul. 21, 2026, which is 72% below its 10-year median of 141.88. GuruFocus rates ASX:IIQ with a GF Score™ of 27/100 and a GF Value™ of A$0.51 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 200 Medical Diagnostics & Research companies, Inoviq ranks worse than 96.5% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Inoviq's share price is A$0.20.
Inoviq's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.01. Hence, Inoviq's PS Ratio for today is 40.00.
Good Sign:
Inoviq Ltd stock PS Ratio (=42) is close to 10-year low of 42.
The historical rank and industry rank for Inoviq's PS Ratio or its related term are showing as below:
ASX:IIQ'
s PS Ratio Range Over the Past 10 Years
Min: 40 Med: 141.88 Max: 323.33
Current: 40
During the past 13 years, Inoviq's highest PS Ratio was 323.33. The lowest was 40.00. And the median was 141.88.
ASX:IIQ's PS Ratio is ranked worse than 96.5% of 200
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.695
vs ASX:IIQ: 40.00
Inoviq's Revenue per Sharefor the
six
months ended in Dec. 2025 was A$0.00.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.01.
Warning Sign:
Inoviq Ltd revenue per share is in decline over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Inoviq was -16.70% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 18.60% per year.
During the past 13 years, Inoviq's highest 3-Year average Revenue per Share Growth Rate was 144.40% per year. The lowest was -93.50% per year. And the median was -26.95% per year.
Back to Basics: PS Ratio
Inoviq (ASX:IIQ) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Inoviq PS Ratio Related Terms
Inoviq PS Ratio Historical Data
* Premium members only.
The historical data trend for Inoviq's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Inoviq's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inoviq PS Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Inoviq's PS Ratio distribution charts can be found below:
* The bar in red indicates where Inoviq's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Inoviq's Share Price of today is A$0.20.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Inoviq's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.01.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Inoviq (ASX:IIQ) has a PS Ratio of 40.00 as of Jul. 21, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Inoviq and its competitors. This is 72% below median its historical median of 141.88. Over the past decade, Inoviq's PS Ratio has ranged from 40.00 to 323.33. According to the industry distribution chart, Inoviq ranks #193 out of 200 companies in the Medical Diagnostics & Research industry, placing it in the top 96.5%.
Is Inoviq's PS Ratio too high?
Inoviq's current PS Ratio of 40.00 is 72% below median its 10-year median of 141.88. Over the past 10 years, this metric has ranged from a low of 40.00 to a high of 323.33. The Medical Diagnostics & Research industry median PS Ratio is 2.70. Inoviq's value of 40.00 is 1384.2% above this industry median. Based on the distribution chart, Inoviq ranks #193 out of 200 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Inoviq has a GF Score™ of 27/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Inoviq's PS Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Inoviq ranks #193 out of 200 companies for PS Ratio. This places Inoviq in the lower half of its industry. The industry median PS Ratio is 2.70. Inoviq's value of 40.00 is 1384.2% above this benchmark. Historically, Inoviq's own PS Ratio has ranged from 40.00 to 323.33 over the past decade. While the company's 10-year median is 141.88 vs. the industry median of 2.70, Inoviq has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Diagnostics & Research company?
The median PS Ratio among Medical Diagnostics & Research companies is 2.70, based on 200 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Inoviq's current PS Ratio of 40.00 is 1384.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Inoviq and its competitors. For the Medical Diagnostics & Research industry, the median PS Ratio is 2.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Inoviq's current PS Ratio is 40.00, which is 72% below median its own 10-year median of 141.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inoviq stock overvalued right now?
Based on GuruFocus' analysis, Inoviq (ASX:IIQ) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.51, compared to a current price of A$0.20 — trading 60.8% below its estimated fair value. The current PS Ratio is 40.00, which is 72% below median its 10-year median of 141.88 and 1384.2% above the Medical Diagnostics & Research industry median of 2.70. Inoviq's overall GF Score™ is 27/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Inoviq (ASX:IIQ), the current PS Ratio is 40.00 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Inoviq (ASX:IIQ) Overvalued in 2026?
Based on GuruFocus' analysis, Inoviq stock appears to be undervalued.
The current stock price of A$0.20 is trading 60.8% below its estimated GF Value™ of A$0.51.
GuruFocus considers Inoviq to be Possible Value Trap.
Key valuation signals for ASX:IIQ:
PS Ratio: 40.00 (72% below median its 10-year median of 141.88)
GF Value™: A$0.51 vs. price of A$0.20 (60.8% below fair value)
Industry Position: 1384.2% above the Medical Diagnostics & Research median (#193 of 200)
No single metric tells the full story. See the ASX:IIQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Inoviq Ltd is engaged in developing and commercializing a portfolio of diagnostic and exosome-based products to improve the diagnosis and treatment of cancer and other diseases. The company has commercialized the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Its cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate, and other cancers. The Group operates predominantly in one business segment, the research and development of cancer diagnostics, and two geographical segments, Victoria, Australia, and the United States of America, with the majority of revenue coming from Australia.
27GF Score
Get the complete analysis for ASX:IIQ
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IIQ has been successfully added to your 
